0.019455 0.000000 0.000000 0.000000 0.017036 0.000000 0.000000 0.000000 0.016129 0.00000 0.00000 0.00000 Wickramasinghe, W. Begun, J. Martin, J.L. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 8 90.00 90.00 90.00 51.400 58.700 62.000 C4 H9 N O2 103.120 n ALPHA-AMINOBUTYRIC ACID L-peptide linking C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking H2 O 18.015 WATER non-polymer C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C5 H11 N O2 S 149.211 y METHIONINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C33 H48 N4 O6 596.757 [1-BENZYL-3-(8-SEC-BUTYL-7,10-DIOXO-2-OXA-6,9-DIAZA-BICYCLO[11.2.2] HEPTADECA-1(16),13(17),14-TRIEN-11-YLAMINO)-2-HYDROXY-PROPYL]-CARBAMIC ACID TERT-BUTYL ESTER MACROCYCLIC PEPTIDOMIMETIC INHIBITOR 6 peptide-like C5 H9 N O2 115.130 y PROLINE L-peptide linking O4 S -2 96.063 SULFATE ION non-polymer C4 H9 N O3 119.119 y THREONINE L-peptide linking C11 H12 N2 O2 204.225 y TRYPTOPHAN L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking US J.Am.Chem.Soc. JACSAT 0004 0002-7863 118 3375 3379 -1 Substrate-based cyclic peptidomimetics of Phe-Ile-Val that inhibit HIV-1 protease using a novel enzyme-binding mode. 1996 10.2210/pdb1mtr/pdb pdb_00001mtr 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 289 1 IMAGE PLATE 1995-03-28 RIGAKU RAXIS IIC M x-ray 1 1.5418 1.0 1.5418 10765.687 HIV-1 PROTEASE 3.4.23.16 2 man polymer 96.063 SULFATE ION 3 syn non-polymer 596.757 [1-BENZYL-3-(8-SEC-BUTYL-7,10-DIOXO-2-OXA-6,9-DIAZA-BICYCLO[11.2.2] HEPTADECA-1(16),13(17),14-TRIEN-11-YLAMINO)-2-HYDROXY-PROPYL]-CARBAMIC ACID TERT-BUTYL ESTER 1 syn non-polymer 18.015 water 115 nat water no yes PQITLWKRPLVTIRIGGQLKEALLDTGADDTVIEEMNLPGKWKPKMIGGIGGFIKVRQYDQIPVEI(ABA)GHKAIGTVL VGPTPVNIIGRNLLTQIG(ABA)TLNF PQITLWKRPLVTIRIGGQLKEALLDTGADDTVIEEMNLPGKWKPKMIGGIGGFIKVRQYDQIPVEIAGHKAIGTVLVGPT PVNIIGRNLLTQIGATLNF A,B polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n Lentivirus Escherichia sample 11676 Human immunodeficiency virus 1 562 Escherichia coli 1 2.11 44. 5.5 pH 5.5 database_2 pdbx_database_status struct_conn struct_ref_seq_dif struct_site pdbx_initial_refinement_model repository Initial release Version format compliance Atomic model Database references Derived calculations Non-polymer description Structure summary Version format compliance Non-polymer description Non-polymer description Non-polymer description Other Database references Derived calculations Other Refinement description 1 0 1996-08-01 1 1 2008-03-24 1 2 2011-07-13 1 3 2011-08-24 1 4 2012-07-25 1 5 2012-09-19 1 6 2012-12-12 1 7 2021-11-03 1 8 2023-08-09 _database_2.pdbx_DOI _database_2.pdbx_database_accession _pdbx_database_status.process_site _struct_conn.pdbx_leaving_atom_flag _struct_conn.ptnr1_auth_comp_id _struct_conn.ptnr1_auth_seq_id _struct_conn.ptnr1_label_atom_id _struct_conn.ptnr1_label_comp_id _struct_conn.ptnr1_label_seq_id _struct_conn.ptnr2_auth_comp_id _struct_conn.ptnr2_auth_seq_id _struct_conn.ptnr2_label_atom_id _struct_conn.ptnr2_label_comp_id _struct_conn.ptnr2_label_seq_id _struct_ref_seq_dif.details _struct_site.pdbx_auth_asym_id _struct_site.pdbx_auth_comp_id _struct_site.pdbx_auth_seq_id Y BNL 1996-02-15 REL SO4 SULFATE ION PI6 [1-BENZYL-3-(8-SEC-BUTYL-7,10-DIOXO-2-OXA-6,9-DIAZA-BICYCLO[11.2.2] HEPTADECA-1(16),13(17),14-TRIEN-11-YLAMINO)-2-HYDROXY-PROPYL]-CARBAMIC ACID TERT-BUTYL ESTER HOH water GLN 7 WAS REPLACED BY LYS TO PREVENT AUTOCLEAVAGE. LEU 33 WAS REPLACED BY ILE TO PREVENT AUTOCLEAVAGE. CYS 67 WAS REPLACED BY ABA FOR EASE OF CHEMICAL SYNTHESIS. CYS 95 WAS REPLACED BY ABA FOR EASE OF CHEMICAL SYNTHESIS. 1CPI PDB experimental model Inhibitor tert-butyl [(1S,2S)-1-benzyl-2-hydroxy-3-{[(8S,11R)-8-[(1R)-1-methylpropyl]-7,10-dioxo-2-oxa-6,9-diazabicyclo[11.2.2]heptadeca-1(15),13,16-trien-11-yl]amino}propyl]carbamate Peptide-like SO4 502 2 SO4 SO4 101 A SO4 503 2 SO4 SO4 102 A PI6 100 3 PI6 PI6 101 B SO4 501 2 SO4 SO4 102 B HOH 302 4 HOH HOH 201 A HOH 306 4 HOH HOH 202 A HOH 307 4 HOH HOH 203 A HOH 311 4 HOH HOH 204 A HOH 312 4 HOH HOH 205 A HOH 313 4 HOH HOH 206 A HOH 314 4 HOH HOH 207 A HOH 318 4 HOH HOH 208 A HOH 319 4 HOH HOH 209 A HOH 327 4 HOH HOH 210 A HOH 329 4 HOH HOH 211 A HOH 332 4 HOH HOH 212 A HOH 333 4 HOH HOH 213 A HOH 334 4 HOH HOH 214 A HOH 335 4 HOH HOH 215 A HOH 339 4 HOH HOH 216 A HOH 341 4 HOH HOH 217 A HOH 342 4 HOH HOH 218 A HOH 344 4 HOH HOH 219 A HOH 345 4 HOH HOH 220 A HOH 346 4 HOH HOH 221 A HOH 349 4 HOH HOH 222 A HOH 351 4 HOH HOH 223 A HOH 353 4 HOH HOH 224 A HOH 362 4 HOH HOH 225 A HOH 374 4 HOH HOH 226 A HOH 375 4 HOH HOH 227 A HOH 376 4 HOH HOH 228 A HOH 377 4 HOH HOH 229 A HOH 378 4 HOH HOH 230 A HOH 380 4 HOH HOH 231 A HOH 381 4 HOH HOH 232 A HOH 382 4 HOH HOH 233 A HOH 383 4 HOH HOH 234 A HOH 384 4 HOH HOH 235 A HOH 385 4 HOH HOH 236 A HOH 388 4 HOH HOH 237 A HOH 389 4 HOH HOH 238 A HOH 390 4 HOH HOH 239 A HOH 391 4 HOH HOH 240 A HOH 393 4 HOH HOH 241 A HOH 394 4 HOH HOH 242 A HOH 396 4 HOH HOH 243 A HOH 399 4 HOH HOH 244 A HOH 400 4 HOH HOH 245 A HOH 403 4 HOH HOH 246 A HOH 405 4 HOH HOH 247 A HOH 406 4 HOH HOH 248 A HOH 409 4 HOH HOH 249 A HOH 411 4 HOH HOH 250 A HOH 414 4 HOH HOH 251 A HOH 415 4 HOH HOH 252 A HOH 416 4 HOH HOH 253 A HOH 301 4 HOH HOH 301 B HOH 303 4 HOH HOH 302 B HOH 304 4 HOH HOH 303 B HOH 305 4 HOH HOH 304 B HOH 308 4 HOH HOH 305 B HOH 309 4 HOH HOH 306 B HOH 310 4 HOH HOH 307 B HOH 315 4 HOH HOH 308 B HOH 316 4 HOH HOH 309 B HOH 317 4 HOH HOH 310 B HOH 320 4 HOH HOH 311 B HOH 321 4 HOH HOH 312 B HOH 322 4 HOH HOH 313 B HOH 323 4 HOH HOH 314 B HOH 324 4 HOH HOH 315 B HOH 325 4 HOH HOH 316 B HOH 326 4 HOH HOH 317 B HOH 328 4 HOH HOH 318 B HOH 330 4 HOH HOH 319 B HOH 331 4 HOH HOH 320 B HOH 336 4 HOH HOH 321 B HOH 337 4 HOH HOH 322 B HOH 338 4 HOH HOH 323 B HOH 340 4 HOH HOH 324 B HOH 343 4 HOH HOH 325 B HOH 347 4 HOH HOH 326 B HOH 348 4 HOH HOH 327 B HOH 350 4 HOH HOH 328 B HOH 352 4 HOH HOH 329 B HOH 354 4 HOH HOH 330 B HOH 355 4 HOH HOH 331 B HOH 356 4 HOH HOH 332 B HOH 357 4 HOH HOH 333 B HOH 358 4 HOH HOH 334 B HOH 359 4 HOH HOH 335 B HOH 360 4 HOH HOH 336 B HOH 361 4 HOH HOH 337 B HOH 363 4 HOH HOH 338 B HOH 364 4 HOH HOH 339 B HOH 365 4 HOH HOH 340 B HOH 366 4 HOH HOH 341 B HOH 367 4 HOH HOH 342 B HOH 368 4 HOH HOH 343 B HOH 369 4 HOH HOH 344 B HOH 370 4 HOH HOH 345 B HOH 371 4 HOH HOH 346 B HOH 372 4 HOH HOH 347 B HOH 373 4 HOH HOH 348 B HOH 379 4 HOH HOH 349 B HOH 386 4 HOH HOH 350 B HOH 387 4 HOH HOH 351 B HOH 392 4 HOH HOH 352 B HOH 395 4 HOH HOH 353 B HOH 397 4 HOH HOH 354 B HOH 398 4 HOH HOH 355 B HOH 401 4 HOH HOH 356 B HOH 402 4 HOH HOH 357 B HOH 404 4 HOH HOH 358 B HOH 407 4 HOH HOH 359 B HOH 408 4 HOH HOH 360 B HOH 410 4 HOH HOH 361 B HOH 413 4 HOH HOH 362 B PRO 1 n 1 PRO 1 A GLN 2 n 2 GLN 2 A ILE 3 n 3 ILE 3 A THR 4 n 4 THR 4 A LEU 5 n 5 LEU 5 A TRP 6 n 6 TRP 6 A LYS 7 n 7 LYS 7 A ARG 8 n 8 ARG 8 A PRO 9 n 9 PRO 9 A LEU 10 n 10 LEU 10 A VAL 11 n 11 VAL 11 A THR 12 n 12 THR 12 A ILE 13 n 13 ILE 13 A ARG 14 n 14 ARG 14 A ILE 15 n 15 ILE 15 A GLY 16 n 16 GLY 16 A GLY 17 n 17 GLY 17 A GLN 18 n 18 GLN 18 A LEU 19 n 19 LEU 19 A LYS 20 n 20 LYS 20 A GLU 21 n 21 GLU 21 A ALA 22 n 22 ALA 22 A LEU 23 n 23 LEU 23 A LEU 24 n 24 LEU 24 A ASP 25 n 25 ASP 25 A THR 26 n 26 THR 26 A GLY 27 n 27 GLY 27 A ALA 28 n 28 ALA 28 A ASP 29 n 29 ASP 29 A ASP 30 n 30 ASP 30 A THR 31 n 31 THR 31 A VAL 32 n 32 VAL 32 A ILE 33 n 33 ILE 33 A GLU 34 n 34 GLU 34 A GLU 35 n 35 GLU 35 A MET 36 n 36 MET 36 A ASN 37 n 37 ASN 37 A LEU 38 n 38 LEU 38 A PRO 39 n 39 PRO 39 A GLY 40 n 40 GLY 40 A LYS 41 n 41 LYS 41 A TRP 42 n 42 TRP 42 A LYS 43 n 43 LYS 43 A PRO 44 n 44 PRO 44 A LYS 45 n 45 LYS 45 A MET 46 n 46 MET 46 A ILE 47 n 47 ILE 47 A GLY 48 n 48 GLY 48 A GLY 49 n 49 GLY 49 A ILE 50 n 50 ILE 50 A GLY 51 n 51 GLY 51 A GLY 52 n 52 GLY 52 A PHE 53 n 53 PHE 53 A ILE 54 n 54 ILE 54 A LYS 55 n 55 LYS 55 A VAL 56 n 56 VAL 56 A ARG 57 n 57 ARG 57 A GLN 58 n 58 GLN 58 A TYR 59 n 59 TYR 59 A ASP 60 n 60 ASP 60 A GLN 61 n 61 GLN 61 A ILE 62 n 62 ILE 62 A PRO 63 n 63 PRO 63 A VAL 64 n 64 VAL 64 A GLU 65 n 65 GLU 65 A ILE 66 n 66 ILE 66 A ABA 67 n 67 ABA 67 A GLY 68 n 68 GLY 68 A HIS 69 n 69 HIS 69 A LYS 70 n 70 LYS 70 A ALA 71 n 71 ALA 71 A ILE 72 n 72 ILE 72 A GLY 73 n 73 GLY 73 A THR 74 n 74 THR 74 A VAL 75 n 75 VAL 75 A LEU 76 n 76 LEU 76 A VAL 77 n 77 VAL 77 A GLY 78 n 78 GLY 78 A PRO 79 n 79 PRO 79 A THR 80 n 80 THR 80 A PRO 81 n 81 PRO 81 A VAL 82 n 82 VAL 82 A ASN 83 n 83 ASN 83 A ILE 84 n 84 ILE 84 A ILE 85 n 85 ILE 85 A GLY 86 n 86 GLY 86 A ARG 87 n 87 ARG 87 A ASN 88 n 88 ASN 88 A LEU 89 n 89 LEU 89 A LEU 90 n 90 LEU 90 A THR 91 n 91 THR 91 A GLN 92 n 92 GLN 92 A ILE 93 n 93 ILE 93 A GLY 94 n 94 GLY 94 A ABA 95 n 95 ABA 95 A THR 96 n 96 THR 96 A LEU 97 n 97 LEU 97 A ASN 98 n 98 ASN 98 A PHE 99 n 99 PHE 99 A PRO 1 n 1 PRO 1 B GLN 2 n 2 GLN 2 B ILE 3 n 3 ILE 3 B THR 4 n 4 THR 4 B LEU 5 n 5 LEU 5 B TRP 6 n 6 TRP 6 B LYS 7 n 7 LYS 7 B ARG 8 n 8 ARG 8 B PRO 9 n 9 PRO 9 B LEU 10 n 10 LEU 10 B VAL 11 n 11 VAL 11 B THR 12 n 12 THR 12 B ILE 13 n 13 ILE 13 B ARG 14 n 14 ARG 14 B ILE 15 n 15 ILE 15 B GLY 16 n 16 GLY 16 B GLY 17 n 17 GLY 17 B GLN 18 n 18 GLN 18 B LEU 19 n 19 LEU 19 B LYS 20 n 20 LYS 20 B GLU 21 n 21 GLU 21 B ALA 22 n 22 ALA 22 B LEU 23 n 23 LEU 23 B LEU 24 n 24 LEU 24 B ASP 25 n 25 ASP 25 B THR 26 n 26 THR 26 B GLY 27 n 27 GLY 27 B ALA 28 n 28 ALA 28 B ASP 29 n 29 ASP 29 B ASP 30 n 30 ASP 30 B THR 31 n 31 THR 31 B VAL 32 n 32 VAL 32 B ILE 33 n 33 ILE 33 B GLU 34 n 34 GLU 34 B GLU 35 n 35 GLU 35 B MET 36 n 36 MET 36 B ASN 37 n 37 ASN 37 B LEU 38 n 38 LEU 38 B PRO 39 n 39 PRO 39 B GLY 40 n 40 GLY 40 B LYS 41 n 41 LYS 41 B TRP 42 n 42 TRP 42 B LYS 43 n 43 LYS 43 B PRO 44 n 44 PRO 44 B LYS 45 n 45 LYS 45 B MET 46 n 46 MET 46 B ILE 47 n 47 ILE 47 B GLY 48 n 48 GLY 48 B GLY 49 n 49 GLY 49 B ILE 50 n 50 ILE 50 B GLY 51 n 51 GLY 51 B GLY 52 n 52 GLY 52 B PHE 53 n 53 PHE 53 B ILE 54 n 54 ILE 54 B LYS 55 n 55 LYS 55 B VAL 56 n 56 VAL 56 B ARG 57 n 57 ARG 57 B GLN 58 n 58 GLN 58 B TYR 59 n 59 TYR 59 B ASP 60 n 60 ASP 60 B GLN 61 n 61 GLN 61 B ILE 62 n 62 ILE 62 B PRO 63 n 63 PRO 63 B VAL 64 n 64 VAL 64 B GLU 65 n 65 GLU 65 B ILE 66 n 66 ILE 66 B ABA 67 n 67 ABA 67 B GLY 68 n 68 GLY 68 B HIS 69 n 69 HIS 69 B LYS 70 n 70 LYS 70 B ALA 71 n 71 ALA 71 B ILE 72 n 72 ILE 72 B GLY 73 n 73 GLY 73 B THR 74 n 74 THR 74 B VAL 75 n 75 VAL 75 B LEU 76 n 76 LEU 76 B VAL 77 n 77 VAL 77 B GLY 78 n 78 GLY 78 B PRO 79 n 79 PRO 79 B THR 80 n 80 THR 80 B PRO 81 n 81 PRO 81 B VAL 82 n 82 VAL 82 B ASN 83 n 83 ASN 83 B ILE 84 n 84 ILE 84 B ILE 85 n 85 ILE 85 B GLY 86 n 86 GLY 86 B ARG 87 n 87 ARG 87 B ASN 88 n 88 ASN 88 B LEU 89 n 89 LEU 89 B LEU 90 n 90 LEU 90 B THR 91 n 91 THR 91 B GLN 92 n 92 GLN 92 B ILE 93 n 93 ILE 93 B GLY 94 n 94 GLY 94 B ABA 95 n 95 ABA 95 B THR 96 n 96 THR 96 B LEU 97 n 97 LEU 97 B ASN 98 n 98 ASN 98 B PHE 99 n 99 PHE 99 B author_and_software_defined_assembly PISA 2 dimeric 5730 -58 9020 A ABA 67 ALPHA-AMINOBUTYRIC ACID A ABA 67 ALA A ABA 95 ALPHA-AMINOBUTYRIC ACID A ABA 95 ALA B ABA 67 ALPHA-AMINOBUTYRIC ACID B ABA 67 ALA B ABA 95 ALPHA-AMINOBUTYRIC ACID B ABA 95 ALA 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 1 A CG LYS 41 A CG LYS 41 1 Y 1 A CD LYS 41 A CD LYS 41 1 Y 1 A CE LYS 41 A CE LYS 41 1 Y 1 A NZ LYS 41 A NZ LYS 41 1 Y 1 A CG LYS 43 A CG LYS 43 1 Y 1 A CD LYS 43 A CD LYS 43 1 Y 1 A CE LYS 43 A CE LYS 43 1 Y 1 A NZ LYS 43 A NZ LYS 43 1 Y 1 B CG LYS 41 B CG LYS 41 1 Y 1 B CD LYS 41 B CD LYS 41 1 Y 1 B CE LYS 41 B CE LYS 41 1 Y 1 B NZ LYS 41 B NZ LYS 41 1 Y 1 B CG LYS 43 B CG LYS 43 1 Y 1 B CD LYS 43 B CD LYS 43 1 Y 1 B CE LYS 43 B CE LYS 43 1 Y 1 B NZ LYS 43 B NZ LYS 43 1 Y 1 B B O O ILE HOH 50 304 2.17 B 1 -8.81 1.40 111.50 102.69 B B B CA N CD PRO PRO PRO 1 1 1 N 1 B GLU 35 -34.50 112.90 18.7 RESIDUES 50 AND 51 IN THE FLAP REGION OF BOTH SUBUNITS ARE DISORDERED AND WERE MODELLED IN TWO CONFORMATIONS. HOWEVER, THESE REGIONS OF THE STRUCTURE HAVE RELATIVELY POOR GEOMETRY. 0.244 0.179 0.179 1.75 8.0 1661 16283 10. 84. 1 2.0 DIFFERENCE FOURIER 1CPI 0.2 1.75 8.0 115 1673 58 0 1500 0.010 1.66 26.1 1.40 1.5 2.0 2.0 2.5 1.75 50. 1MTR 16528 1. 0.068 1 10.5 5.3 85.9 0.219 1.75 2.0 2.42 1 2.5 69.2 model building X-PLOR 3.1 refinement X-PLOR 3.1 data reduction PROCESS (HIGASHI/RIGAKU) data scaling PROCESS phasing X-PLOR 3.1 HIV-1 PROTEASE COMPLEXED WITH A CYCLIC PHE-ILE-VAL PEPTIDOMIMETIC INHIBITOR 1 N N 1 N N 2 N N 2 N N 3 N N 2 N N 4 N N 4 N N A GLY 86 A GLY 86 HELX_P A GLY 94 A GLY 94 1 HA 9 B GLY 86 B GLY 86 HELX_P B GLY 94 B GLY 94 1 HB 9 covale 1.330 both A ILE 66 A C ILE 66 1_555 A ABA 67 A N ABA 67 1_555 covale 1.325 both A ABA 67 A C ABA 67 1_555 A GLY 68 A N GLY 68 1_555 covale 1.321 both A GLY 94 A C GLY 94 1_555 A ABA 95 A N ABA 95 1_555 covale 1.328 both A ABA 95 A C ABA 95 1_555 A THR 96 A N THR 96 1_555 covale 1.332 both B ILE 66 B C ILE 66 1_555 B ABA 67 B N ABA 67 1_555 covale 1.331 both B ABA 67 B C ABA 67 1_555 B GLY 68 B N GLY 68 1_555 covale 1.332 both B GLY 94 B C GLY 94 1_555 B ABA 95 B N ABA 95 1_555 covale 1.328 both B ABA 95 B C ABA 95 1_555 B THR 96 B N THR 96 1_555 HYDROLASE/HYDROLASE INHIBITOR ASPARTYL PROTEINASE, AIDS, ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR complex POL_HV1A2 UNP 1 1 P03369 FFREDLAFLQGKAREFSSEQTRANSPTRRELQVWGGENNSLSEAGADRQGTVSFNFPQITLWQRPLVTIRIGGQLKEALL DTGADDTVLEEMNLPGKWKPKMIGGIGGFIKVRQYDQIPVEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNFPISPI ETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQ DFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMT KILEPFRKQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIM LPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLLRGTKALTEVIPLTEEAELELAENREILKEPVHEVYYDPSKDL VAEIQKQGQGQWTYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQKVSTESIVIWGKIPKFKLPIQKETWEAWWMEY WQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRETKLGKAGYVTDRGRQKVVSIADTTNQKTELQAIHLA LQDSGLEVNIVTDSQYALGIIQAQPDKSESELVSQIIEQLIKKEKVYLAWVPAHKGIGGNEQVDKLVSAGIRKVLFLNGI DKAQEEHEKYHSNWRAMASDFNLPPVVAKEIVASCDKCQLKGEAMHGQVDCSPGIWQLDCTHLEGKIILVAVHVASGYIE AEVIPAETGQETAYFLLKLAGRWPVKTIHTDNGSNFTSTTVKAACWWAGIKQEFGIPYNPQSQGVVESMNNELKKIIGQV RDQAEHLKTAVQMAVFIHNFKRKGGIGGYSAGERIVDIIATDIQTKELQKQITKIQNFRVYYRDNKDPLWKGPAKLLWKG EGAVVIQDNSDIKVVPRRKAKIIRDYGKQMAGDDCVASRQDED 57 155 1MTR 1 99 P03369 A 1 1 99 57 155 1MTR 1 99 P03369 B 1 1 99 1 GLN engineered mutation LYS 7 1MTR A P03369 UNP 63 7 1 LEU engineered mutation ILE 33 1MTR A P03369 UNP 89 33 1 CYS engineered mutation ABA 67 1MTR A P03369 UNP 123 67 1 CYS engineered mutation ABA 95 1MTR A P03369 UNP 151 95 2 GLN engineered mutation LYS 7 1MTR B P03369 UNP 63 7 2 LEU engineered mutation ILE 33 1MTR B P03369 UNP 89 33 2 CYS engineered mutation ABA 67 1MTR B P03369 UNP 123 67 2 CYS engineered mutation ABA 95 1MTR B P03369 UNP 151 95 8 8 4 anti-parallel anti-parallel parallel anti-parallel parallel anti-parallel anti-parallel anti-parallel anti-parallel parallel anti-parallel parallel anti-parallel anti-parallel anti-parallel anti-parallel anti-parallel A LYS 43 A LYS 43 A GLY 49 A GLY 49 A GLY 52 A GLY 52 A ILE 66 A ILE 66 A HIS 69 A HIS 69 A GLY 78 A GLY 78 A THR 31 A THR 31 A GLU 34 A GLU 34 A ASN 83 A ASN 83 A ILE 85 A ILE 85 A GLN 18 A GLN 18 A ASP 25 A ASP 25 A PRO 9 A PRO 9 A ILE 15 A ILE 15 A GLU 65 A GLU 65 A ILE 66 A ILE 66 B LYS 43 B LYS 43 B GLY 49 B GLY 49 B GLY 52 B GLY 52 B ILE 66 B ILE 66 B HIS 69 B HIS 69 B GLY 78 B GLY 78 B THR 31 B THR 31 B GLU 34 B GLU 34 B ASN 83 B ASN 83 B ILE 85 B ILE 85 B GLN 18 B GLN 18 B ASP 25 B ASP 25 B PRO 9 B PRO 9 B ILE 15 B ILE 15 B GLU 65 B GLU 65 B ILE 66 B ILE 66 A PRO 1 A PRO 1 A THR 4 A THR 4 B THR 96 B THR 96 B PHE 99 B PHE 99 A THR 96 A THR 96 A PHE 99 A PHE 99 B PRO 1 B PRO 1 B THR 4 B THR 4 BINDING SITE FOR RESIDUE SO4 A 101 A SO4 101 Software 2 BINDING SITE FOR RESIDUE SO4 A 102 A SO4 102 Software 8 BINDING SITE FOR RESIDUE PI6 B 101 B PI6 101 Software 19 BINDING SITE FOR RESIDUE SO4 B 102 B SO4 102 Software 5 A PRO 1 A PRO 1 2 1_555 A HIS 69 A HIS 69 2 1_555 A ARG 14 A ARG 14 8 1_555 A GLY 17 A GLY 17 8 1_555 A HOH 245 G HOH 8 1_555 B ARG 14 B ARG 14 8 1_455 B ILE 15 B ILE 15 8 1_455 B GLY 16 B GLY 16 8 1_455 B GLY 17 B GLY 17 8 1_455 B HOH 308 H HOH 8 1_455 A ARG 8 A ARG 8 19 1_555 A LEU 23 A LEU 23 19 1_555 A ASP 25 A ASP 25 19 1_555 A GLY 27 A GLY 27 19 1_555 A GLY 48 A GLY 48 19 1_555 A GLY 49 A GLY 49 19 1_555 A ILE 50 A ILE 50 19 1_555 A PRO 81 A PRO 81 19 1_555 A VAL 82 A VAL 82 19 1_555 B ARG 8 B ARG 8 19 1_555 B ASP 25 B ASP 25 19 1_555 B GLY 27 B GLY 27 19 1_555 B ALA 28 B ALA 28 19 1_555 B ASP 29 B ASP 29 19 1_555 B GLY 48 B GLY 48 19 1_555 B ILE 50 B ILE 50 19 1_555 B PRO 81 B PRO 81 19 1_555 B HOH 301 H HOH 19 1_555 B HOH 325 H HOH 19 1_555 A HIS 69 A HIS 69 5 3_545 A LYS 70 A LYS 70 5 3_545 A HOH 249 G HOH 5 3_545 B PRO 1 B PRO 1 5 2_554 B LYS 55 B LYS 55 5 1_555 19 P 21 21 21